| Indicators | Browse All

Lisata Therapeutics, Inc. (LSTA)

Healthcare | Biotechnology | Basking Ridge, United States | NasdaqCM
3.70 USD +0.43 (13.150%) ⇧ (July 13, 2026, 4 p.m. EDT)
After hours: 3.70

Short-term:★★⯪☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 4:21 a.m. EDT

The immediate catalyst here is the definitive agreement for acquisition by Kuva Labs at $4.00 per share, which represents a significant premium to the current trading price of roughly $3.27. This deal provides a clear near-term floor and a defined upside target, making the short-term outlook neutral-to-slightly-positive as the market digests the terms and potential regulatory hurdles. However, the long-term investment case is severely compromised by a decade-long structural decline; the stock has lost nearly 97% of its value over the last nine years, with seven consecutive years of negative annual returns, indicating a business model that has failed to generate sustainable growth or profitability. Furthermore, the company is burning cash with negative operating margins and no history of paying dividends, leaving no safety net for investors who might wait out the acquisition process. While the buyout offers a resolution, the underlying fundamentals suggest this is a distressed asset rather than a growth story.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.049895
AutoETS0.064623
AutoARIMA0.064625
AutoTheta0.132030

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 34%
H-stat 11.55
Ljung-Box p 0.000
Jarque-Bera p 0.182
Excess Kurtosis -1.34
Attribute Value
Sector Healthcare
Revenue per Share 0.019
Market Cap 33,693,648
Forward P/E -3.19
Beta 0.80
Previous Name Caladrius Biosciences, Inc.
Website https://www.lisata.com

Info Dump

Attribute Value
52 Week Change 0.24334598
Address1 110 Allen Road
Address2 2nd Floor
All Time High 637,500.0
All Time Low 1.81
Ask 3.74
Ask Size 1
Average Daily Volume10 Day 27,520
Average Daily Volume3 Month 111,993
Average Volume 111,993
Average Volume10Days 27,520
Beta 0.795
Bid 3.33
Bid Size 3
Book Value 1.2
City Basking Ridge
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 3.7
Current Ratio 4.229
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 3.9
Day Low 3.3
Display Name Lisata Therapeutics
Earnings Call Timestamp End 1,762,464,600
Earnings Call Timestamp Start 1,762,464,600
Earnings Timestamp End 1,786,046,400
Earnings Timestamp Start 1,786,046,400
Ebitda -17,199,000
Ebitda Margins 0.0
Enterprise To Ebitda -1.185
Enterprise To Revenue 119.88
Enterprise Value 20,379,646
Eps Current Year -1.09
Eps Forward -1.16
Eps Trailing Twelve Months -2.1
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 3.326
Fifty Day Average Change 0.37400007
Fifty Day Average Change Percent 0.1124474
Fifty Two Week Change Percent 24.334599
Fifty Two Week High 5.07
Fifty Two Week High Change -1.3700001
Fifty Two Week High Change Percent -0.27021697
Fifty Two Week Low 1.81
Fifty Two Week Low Change 1.8900001
Fifty Two Week Low Change Percent 1.044199
Fifty Two Week Range 1.81 - 5.07
Financial Currency USD
First Trade Date Milliseconds 920,298,600,000
Float Shares 7,204,339
Forward Eps -1.16
Forward P E -3.1896553
Free Cashflow -8,225,000
Full Exchange Name NasdaqCM
Full Time Employees 21
Gmt Off Set Milliseconds -14,400,000
Gross Margins 1.0
Gross Profits 170,000
Has Pre Post Market Data 1
Held Percent Insiders 0.20887
Held Percent Institutions 0.114259996
Implied Shares Outstanding 9,106,391
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,663,200,000
Last Split Factor 1:15
Long Business Summary Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Long Name Lisata Therapeutics, Inc.
Market us_market
Market Cap 33,693,648
Market State PREPRE
Max Age 86,400
Message Board Id finmb_338272
Most Recent Quarter 1,774,915,200
Name Change Date 2,026-07-13
Net Income To Common -16,351,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 29,777,898
Number Of Analyst Opinions 1
Open 3.3
Operating Cashflow -13,630,000
Operating Margins -101.78824
Payout Ratio 0.0
Peg Ratio 118.4
Phone 908 842 0100
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 3.7
Post Market Time 1,783,980,092
Prev Name Caladrius Biosciences, Inc.
Previous Close 3.27
Price Eps Current Year -3.3944952
Price Hint 4
Price To Book 3.0833333
Price To Sales Trailing12 Months 198.19794
Profit Margins 0.0
Quick Ratio 4.0
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.43
Regular Market Change Percent 13.1498
Regular Market Day High 3.9
Regular Market Day Low 3.3
Regular Market Day Range 3.3 - 3.9
Regular Market Open 3.3
Regular Market Previous Close 3.27
Regular Market Price 3.7
Regular Market Time 1,783,972,801
Regular Market Volume 163,398
Return On Assets -0.50256
Return On Equity -0.91413003
Revenue Per Share 0.019
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 9,106,391
Shares Percent Shares Out 0.0115
Shares Short 104,813
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 124,163
Short Name Lisata Therapeutics, Inc.
Short Percent Of Float 0.0139
Short Ratio 0.83
Source Interval 15
State NJ
Symbol LSTA
Target High Price 4.0
Target Low Price 4.0
Target Mean Price 4.0
Target Median Price 4.0
Total Cash 13,060,000
Total Cash Per Share 1.434
Total Debt 0
Total Revenue 170,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.1
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 3.26245
Two Hundred Day Average Change 0.43755007
Two Hundred Day Average Change Percent 0.13411702
Type Disp Equity
Volume 163,398
Website https://www.lisata.com
Zip 7,920